Physician profile
Rami E Geffner
NPI 1366491110
$1,227.37
in general payments reported to CMS, 2019-2025
26 companies · $47.74 in 2025
The $47.74 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $480 · 2020: $198 · 2021: $170 · 2022: $139 · 2023: $161 · 2024: $31.93 · 2025: $47.74.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $241.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $240.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $276.72 | 2019 | |
| Abbvie INC. | $144.00 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $130.24 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $86.75 | 2019-2025 | |
| Leo Pharma INC. | $72.24 | 2020-2022 | |
| Amgen INC. | $62.21 | 2020-2023 | Otezla |
| Organogenesis INC. | $46.76 | 2021-2023 | Puraply |
| Genentech USA, INC. | $44.17 | 2021-2022 | |
| Encore Dermatology INC. | $40.94 | 2019 | |
| Hill Dermaceuticals, INC. | $34.28 | 2025 | Tolak |
| Epi Health, LLC | $33.37 | 2020-2022 | |
| Misonix INC | $29.44 | 2021 | |
| Janssen Biotech, INC. | $29.04 | 2021-2024 | Tremfya |
| Allergan, INC. | $25.96 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $17.68 | 2024 | Sotyktu |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $17.16 | 2023 | Vtama |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $14.92 | 2019 | |
| Lilly USA, LLC | $14.81 | 2022 | |
| Almirall LLC | $14.62 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $14.10 | 2021 | |
| Merck Sharp & Dohme LLC | $13.85 | 2019 | |
| Ucb, INC. | $13.50 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $13.29 | 2022 | |
| Genzyme Corporation | $13.02 | 2022 | |
| Galderma Laboratories, L.P. | $12.36 | 2020 | |
| Pfizer INC. | $11.94 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rami Geffner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.